このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

英国(英国)において、小児用投与装置を使用して投与されたアフリベルセプト(アイリーア)が未熟児網膜症の早産児にどのように使用されているかに関するデータを収集するための観察研究

2026年11月4日 更新者:Bayer

英国における未熟児網膜症の早産児におけるPICLEO小児用投与装置を使用したEylea 40 mg/mLの薬物利用研究

This is an observational study in which only data from babies with retinopathy of prematurity (ROP) who are being treated with aflibercept (Eylea) in prefilled syringe (PFS) using a paediatric dosing device (PDD) are collected and studied.

ROP is a condition that affects the eyes of preterm babies. It occurs when the baby's retina, the part of the eye that senses light, does not develop normally. This may result in vision problems, including blindness, if left untreated. Preterm babies are born before 37 weeks of pregnancy. ROP is more likely to develop in babies who are born before 32 weeks of pregnancy or weigh less than 1.5 kilograms at birth.

Aflibercept is a drug that is injected into the eye. It works by blocking a protein called vascular endothelial growth factor (VEGF) which causes abnormal growth of blood vessels in the retina.

Aflibercept in PFS given using a PDD is approved for the treatment of babies with ROP. The prefilled syringe will be fitted with an injection needle to give aflibercept. And a PDD is a tool used to give the right amount of aflibercept to children in a safe manner.

Since there are other treatments which are commonly used for babies with ROP, the extent of use of aflibercept given using a PDD is unknown.

The main purpose of this study is to:

  • find the number of preterm babies who are treated with aflibercept using a PDD in the UK
  • inform whether this number is enough to perform a study to learn about the long-term safety of aflibercept given using a PDD in babies with ROP

An additional purpose of this study is to describe characteristics including age, sex, and race, and signs and symptoms of ROP observed in babies being treated with aflibercept using a PDD.

The data will come from a database called the National Neonatal Research Database. The study will cover the period from March 2024 to March 2025, if the number of babies found is enough to perform the safety study. If not, data will be collected till April 2027.

In this study only available data from preterm babies born during the study period are collected. No visits or tests are required as part of this study.

調査の概要

状態

募集

研究の種類

観察的

入学 (推定)

200

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Many Locations、イギリス
        • 募集
        • Many locations

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1年歳未満 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

All premature infants diagnosed with ROP and treated with Eylea PFS + PDD included in the National Neonatal Research Database (NNRD) during the study period in the UK.

説明

Inclusion Criteria:

  • Eligible infants within the NNRD include those who were:

    • 1. Born during the study period, i.e. from Q4/2023 following market introduction of Eylea PFS+PDD and 31st December 2026, and
    • 2. Received care in a neonatal unit that contributes data to the NNRD and the unit has agreed to participate in the study, and
    • 3. Diagnosed with ROP in any stage in at least one eye.

Exclusion Criteria:

  • Infants with missing data for gestational age at birth will be excluded.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:CROSS_SECTIONAL

コホートと介入

グループ/コホート
介入・治療
Premature infants diagnosed with ROP

Premature infants diagnosed with retinopathy of prematurity (ROP) and treated with aflibercept 0.4 mg using the Eylea 40 mg/mL prefilled syringe (PFS) in combination with the PICLEO paediatric dosing device (PDD) after marketing authorisation in UK and included in the National Neonatal Research Database (NNRD).

Eylea 40 mg/mL solution for injection in pre-filled syringe.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of participants treated with Eylea PFS+PDD upon completion of 1- or 3-years following market introduction
時間枠:From market introduction of Eylea PFS+PDD in UK up to 3 years
  • To evaluate trends in drug utilization patterns of Eylea prefilled syringe (PFS)+Paediatric Dosing Device (PDD) in the ROP patient population. Exposure to Eylea is defined as a record of Eylea PFS+PDD in the National Neonatal Research Database (NNRD) database during admission to the neonatal unity during the study period.
  • To inform the decision on whether the number of preterm infants with ROP exposed to Eylea PFS+PDD is sufficient (n=200) for proceeding with a cohort study to collect data on long-term safety (ocular and systemic safety including neurodevelopmental outcome).
From market introduction of Eylea PFS+PDD in UK up to 3 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Summary of patient characteristics reported as number of participants with different categories
時間枠:From market introduction of Eylea PFS+PDD in UK up to 3 years

Birth weight (in categories), sex, gestational age in weeks (in categories), ethnicity, etc.

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of maternal factors reported as number of participants with different categories
時間枠:From market introduction of Eylea PFS+PDD in UK up to 3 years

Problems during pregnancy with mother, problems during pregnancy, mode of delivery, meconium stained liquor at delivery, etc.

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of comorbidities reported as number of participants with different categories
時間枠:From market introduction of Eylea PFS+PDD in UK up to 3 years

Brain injury, necrotising enterocholitis, pulmonary hemorrhage, chronic lung disease, etc.

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of clinical condition and resource utilization reported as number of participants with different categories
時間枠:From market introduction of Eylea PFS+PDD in UK up to 3 years

Respiratory support (mode of ventilation), cardiovascular (inotropic support), feeding (parenteral and enteral nutrition)

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of clinical condition and resource utilization reported as days
時間枠:From market introduction of Eylea PFS+PDD in UK up to 3 years

Intensive care days, invasive ventilation days, parenteral nutrition days

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of outcomes of the premature infants reported as number of participants with different categories
時間枠:From market introduction of Eylea PFS+PDD in UK up to 3 years

Survival to discharge from neonatal care (Y/N); Discharge, death, transferred to another hospital (in categories)

From market introduction of Eylea PFS+PDD in UK up to 3 years
Summary of ocular disease and treatment reported as number of participants with different categories
時間枠:From market introduction of Eylea PFS+PDD in UK up to 3 years

Number of Eylea injections in the neonatal unity, ROP surgery, ROP stage, ROP clock hours, ROP Max zone, etc.

From market introduction of Eylea PFS+PDD in UK up to 3 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年3月5日

一次修了 (推定)

2027年3月31日

研究の完了 (推定)

2027年4月30日

試験登録日

最初に提出

2024年2月26日

QC基準を満たした最初の提出物

2024年3月11日

最初の投稿 (実際)

2024年3月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年11月4日

最終確認日

2026年11月4日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する